Vico Therapeutics
PrivateLast Round
Series B
Extension
Jun 24, 2024
Total Funding Raised
$114.1M
Company Overview
Vico Therapeutics is a biotechnology company that develops RNA-modulating antisense oligonucleotide (ASO) therapies aimed at treating patients with severe, rare neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vico Therapeutics Comparables
Compare Vico Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Wave Life Sciences | 81% | |
| ProQR Therapeutics | 79% | |
| Stoke Therapeutics, Inc. | 76% |
Vico Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jun 24, 2024 | ||||
| Series B | Jan 5, 2024 | ||||
| Series A | Jul 29, 2020 |
Vico Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ackermans & van Haaren | Series B Extension, Series B |
| EQT Life Sciences | Series B Extension, Series A, Series B |
| Idinvest Partners | Series A |
| Seroba Life Sciences | Series B Extension |
| Pontifax Credit | Series A |
| Droia Ventures | Series B Extension, Series A, Series B |
| Pureos Bioventures | Series A, Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Product candidate VO659 is undergoing a first-in-human study for rare neurological disorders.
- Jun 22, 2025
Job posting indicates preparation for IPO as part of growth strategy.
Vico Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vico Therapeutics's valuation, stock price, and market status.
Is Vico a public or private company?
Vico is a private company.
What is the current stock price of Vico?
Vico is a private company with no public stock price. No recent secondary market data is available.
How much is Vico worth (valuation)?
Valuation information for Vico is not publicly available.
Can I buy Vico stock?
Vico shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Vico's last funding round?
Vico's most recent funding round was Series B Extension on June 24, 2024.
Who are the main investors in Vico?
Key investors in Vico include Ackermans & van Haaren, EQT Life Sciences, Eurazeo, Kurma Partners.
Will Vico IPO soon?
No public IPO plans have been announced for Vico.
How can I track Vico secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vico's secondary market activity and sign up for updates.